Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
(NASDAQ:SLGL), NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update following the unblinding of clinical data from its vehicle-controlled proof-of-concept Phase 1b study of SGT-210 on Darier disease. Following unblinding, the data from […]